CD274 and neoplasm: Anti‐PD‐1/PD‐L1 therapy was an approach to ‘‘immune normalization,” which selectively restored the tumor‐induced immune deficiency in the tumor microenvironment (TME) with fewer immune‐related adverse events (irAEs).6